Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.66 |
| ▸ | CA1 | P00915 | 2/20 | 0.66 |
| ▸ | CA2 | P00918 | 2/20 | 0.66 |
| ▸ | CA7 | P43166 | 1/20 | 0.66 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29437178 | 1.00 | CA12 (0.66) | CA12CA1CA2CA7CA14 | |
| SCHEMBL2330175 | 0.96 | CA12 (0.60) | CA12CA1CA2CA7CA14 | |
| SCHEMBL10118335 | 0.94 | CA12 (0.58) | CA12CA1CA2CA7CA14 | |
| SCHEMBL19682813 | 0.80 | MAOA (0.47) | CA12CA1CA2CA7CA14 | |
| SCHEMBL29519756 | 0.79 | CA1 (1.00) | CA12CA1CA2CA7CA14 | |
| SCHEMBL2011443 | 0.79 | CA1 (1.00) | CA12CA1CA2CA7CA14 | |
| SCHEMBL12828070 | 0.79 | CA12 (0.66) | CA12CA1CA2CA7CA14 | |
| SCHEMBL2634017 | 0.79 | CA1 (0.66) | CA12CA1CA2CA7CA14 | |
| SCHEMBL7909284 | 0.79 | CA12 (0.66) | CA12CA1CA2CA7CA14 | |
| Hydrochloric Acid SCHEMBL4235994 | 0.78 | CA1 (0.63) | CA12CA1CA2CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119912662-A | Epoxy resin curing agent for insulating castable and preparation method thereof | 江苏三木化工股份有限公司 | 2025-05-02 | — | — | CN | claimed |
| CN-119912663-A | Epoxy resin curing agent for corrosion prevention of stripping tower and preparation method thereof | 江苏三木化工股份有限公司 | 2025-05-02 | — | — | CN | claimed |
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | disclosed |
| US-12570632-B2 | Indole derivatives and uses thereof for treating a cancer | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2026-03-10 | — | — | US | disclosed |
| US-12391647-B2 | Benzamide compound and preparation method, use, and pharmaceutical composition thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2025-08-19 | — | — | US | disclosed |
| WO-2025136811-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | IDEAYA BIOSCIENCES, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-119912663-A | Epoxy resin curing agent for corrosion prevention of stripping tower and preparation method thereof | 江苏三木化工股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-119912662-A | Epoxy resin curing agent for insulating castable and preparation method thereof | 江苏三木化工股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| EP-4175718-B1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIV CLAUDE BERNARD LYON (FR) | 2024-10-02 | — | — | EP | disclosed |
| EP-4335439-A2 | COMPOUNDS | CTXT PTY LTD (AU) | 2024-03-13 | — | — | EP | disclosed |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-6787534-B2 | SUBSTITUTED QUINOLINE AND ISOQUINOLINE ANTIANGIOGENIC AGENTS; SULFONYLUREAS | EISAI CO., LTD. (JP) | 2004-09-07 | — | — | US | disclosed |
| EP-1445250-A1 | NOVEL AMINE DERIVATIVE HAVING HUMAN BETA-TRYPTASE INHIBITORY ACTIVITY AND DRUGS CONTAINING THE SAME | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-11 | — | — | EP | disclosed |
| WO-2004048329-A1 | ANTITUMOR BENZOYLSULFONAMIDES | ELI LILLY AND COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20040018192-A1 | Integrin expression inhibitors | EISAI CO., LTD. (JP) | 2004-01-29 | — | — | US | disclosed |
| US-20030144507-A1 | Sulfonamide-containing heterocyclic compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-1258252-A1 | INTEGRIN EXPRESSION INHIBITORS | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| EP-1243583-A1 | HETEROCYCLIC COMPOUNDS HAVING SULFONAMIDE GROUPS | Eisai Co., Ltd. (JP) | 2002-09-25 | — | — | EP | disclosed |
| US-6333338-B1 | ANTICOAGULANTS, CARDIOVASCULAR DISORDERS | LABORATOIRE L. LAFON (FR) | 2001-12-25 | — | — | US | disclosed |
| US-4265633-A | Process for the manufacture of vat dyes | CIBA-GEIGY AG (CH) | 1981-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | CA12 4051/4885CA1 3553/4885CA2 1341/4885 |
| US-12391647-B2 | Benzamide compound and preparation method, use, and pharmaceutical composition thereof | JAK2, STAT3, STAT5A | CA12 1794/4885CA1 1768/4885CA2 573/4885 |
| US-12570632-B2 | Indole derivatives and uses thereof for treating a cancer | CKS2, CSNK2A3, CSNK1A1L | CA12 414/4885CA1 476/4885CA2 274/4885 |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NR1H4 | CA12 4873/4885CA1 4785/4885CA2 4756/4885 |
| US-20040018192-A1 | Integrin expression inhibitors | ITGB1, ITGB4, ITGB5 | CA12 535/4885CA1 827/4885CA2 631/4885 |
| US-20030144507-A1 | Sulfonamide-containing heterocyclic compounds | SLC5A2, SLC5A1, CBR3 | CA12 224/4885CA1 302/4885CA2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.